A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
NCT07274813
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
RECRUITING
Status
254
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced/Metastatic Solid Tumors
NSCLC
Interventions
DRUG:
HLX37
Sponsor
Shanghai Henlius Biotech